神经病变型戈谢病的管理：欧洲共识 - Suppr

Suppr

超能文献

Management of neuronopathic Gaucher disease: a European consensus.

作者信息

Vellodi A, Bembi B, de Villemeur T B, Collin-Histed T, Erikson A, Mengel E, Rolfs A, Tylki-Szymanska A

机构信息

Metabolic Unit, Great Ormond Street Hospital for Children, London, UK.

出版信息

J Inherit Metab Dis. 2001 Jun;24(3):319-27. doi: 10.1023/a:1010514614570.

DOI:10.1023/a:1010514614570

PMID:11486896

Abstract

摘要

相似文献

Management of neuronopathic Gaucher disease: a European consensus.

J Inherit Metab Dis. 2001 Jun;24(3):319-27. doi: 10.1023/a:1010514614570.

Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease.

Clin Genet. 1998 Sep;54(3):179-84. doi: 10.1111/j.1399-0004.1998.tb04281.x.

Management of neuronopathic Gaucher disease: revised recommendations.

J Inherit Metab Dis. 2009 Oct;32(5):660-664. doi: 10.1007/s10545-009-1164-2. Epub 2009 Aug 5.

[Gaucher disease in childhood].

Rev Med Interne. 2007 Oct;28 Suppl 2:S183-6. doi: 10.1016/s0248-8663(07)78879-3.

Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement.

Skeletal Radiol. 1997 Dec;26(12):687-96. doi: 10.1007/s002560050313.

Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.

J Pediatr. 2004 Jan;144(1):112-20. doi: 10.1016/j.jpeds.2003.10.067.

[Current therapeutic focus in type I Gaucher's disease].

Sangre (Barc). 1994 Feb;39(1):39-44.

Gaucher disease: enzyme therapy in the acute neuronopathic variant.

Am J Med Genet. 1997 Jul 11;71(1):16-21.

Gaucher disease: lessons from a decade of therapy.

J Pediatr. 2004 May;144(5 Suppl):S15-9. doi: 10.1016/j.jpeds.2004.01.050.

[Treatment of type 1 Gaucher's disease. Still a long way to go].

Med Clin (Barc). 2000 May 27;114(20):774-6. doi: 10.1016/s0025-7753(00)71434-5.

引用本文的文献

AAV-mediated GBA1 and GDNF rescue neurological defects in a murine model of neuronopathic Gaucher disease.

Mol Ther Nucleic Acids. 2025 Mar 7;36(2):102506. doi: 10.1016/j.omtn.2025.102506. eCollection 2025 Jun 10.

A global neuronopathic gaucher disease registry (GARDIAN): a patient-led initiative.

Orphanet J Rare Dis. 2023 Jul 21;18(1):195. doi: 10.1186/s13023-023-02828-w.

Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey.

JIMD Rep. 2022 Nov 8;64(1):90-103. doi: 10.1002/jmd2.12342. eCollection 2023 Jan.

GBA mutations in Gaucher type I Venezuelan patients: ethnic origins and frequencies.

J Genet. 2017 Sep;96(4):583-589. doi: 10.1007/s12041-017-0821-8.

Previously unrecognized behavioral phenotype in Gaucher disease type 3.

Neurol Genet. 2017 May 23;3(3):e158. doi: 10.1212/NXG.0000000000000158. eCollection 2017 Jun.

Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.

Mol Ther. 2017 May 3;25(5):1155-1162. doi: 10.1016/j.ymthe.2017.03.025. Epub 2017 Apr 4.

Gaucher Disease in Two Siblings.

Med J Armed Forces India. 2008 Oct;64(4):369-70. doi: 10.1016/S0377-1237(08)80028-7. Epub 2011 Jul 21.

Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.

Clin Pharmacokinet. 2016 Sep;55(9):1103-13. doi: 10.1007/s40262-016-0387-2.

Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Orphanet J Rare Dis. 2015 Dec 30;10:164. doi: 10.1186/s13023-015-0376-9.

Neurogenic bladder dysfunction presenting as urinary retention in neuronopathic Gaucher disease.

JIMD Rep. 2015;15:67-70. doi: 10.1007/8904_2014_299. Epub 2014 Mar 25.

本文引用的文献

Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease.

Clin Biochem. 2000 Mar;33(2):147-9. doi: 10.1016/s0009-9120(99)00098-3.

Ocular motor abnormalities in Gaucher disease.

Neuropediatrics. 1999 Dec;30(6):289-93. doi: 10.1055/s-2007-973507.

Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation.

Hum Genet. 1999 Jul-Aug;105(1-2):120-6. doi: 10.1007/s004399900076.

Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease.

Clin Genet. 1998 Sep;54(3):179-84. doi: 10.1111/j.1399-0004.1998.tb04281.x.

Neuronopathic forms of Gaucher's disease.

Baillieres Clin Haematol. 1997 Dec;10(4):711-23. doi: 10.1016/s0950-3536(97)80035-2.

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

Ann Neurol. 1997 Oct;42(4):613-21. doi: 10.1002/ana.410420412.

Gaucher disease: enzyme therapy in the acute neuronopathic variant.

Am J Med Genet. 1997 Jul 11;71(1):16-21.

Types I and III Gaucher disease in Poland: incidence of the most common mutations and phenotypic manifestations.

Eur J Hum Genet. 1996;4(6):334-7. doi: 10.1159/000472228.

Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.

Neurology. 1993 Oct;43(10):1993-7. doi: 10.1212/wnl.43.10.1993.

Enzyme replacement therapy of infantile Gaucher disease.

Neuropediatrics. 1993 Aug;24(4):237-8. doi: 10.1055/s-2008-1071549.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验